ROSWELL, Ga., September 8, 2025 — Saol Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for SL1009, Sodium Dichloroacetate Oral Solution (DCA), intended for the treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD). Despite the CRL, Saol remains committed to addressing the FDA’s observations and is seeking a path forward that does not require an additional Phase 3 trial.
Science Significance
SL1009 is an investigational treatment for PDCD, a rare and life-threatening mitochondrial disorder characterized by chronic energy deficits, leading to lactic acidosis and severe developmental issues. The FDA granted SL1009 Orphan Drug, Priority Review, and Rare Pediatric Disease Designations, underscoring the urgent need for therapeutic options in this patient population. The CRL includes specific observations that Saol must address to clarify the path forward, though no issues were raised regarding the manufacturing of SL1009.
Regulatory Significance
The CRL indicates that while SL1009 shows promise, additional data or clarification is required to meet the FDA’s standards for approval. Saol is requesting a Type A meeting with the FDA to discuss the observations and explore potential pathways to approval that do not necessitate another Phase 3 trial. This engagement reflects the FDA’s commitment to regulatory flexibility in addressing the needs of rare diseases.
Business Significance
Advertisement
The CRL presents a setback for Saol Therapeutics, potentially delaying the anticipated approval of SL1009. However, the company’s proactive approach in seeking a meeting with the FDA demonstrates a commitment to advancing the development of SL1009. The outcome of this dialogue will significantly influence Saol’s strategic direction and could impact investor confidence and market positioning.
Patients’ Significance
For patients with PDCD, the absence of FDA-approved treatments makes SL1009 a critical potential therapy. The CRL may delay access to this investigational treatment, prolonging the uncertainty and challenges faced by patients and their families. Saol’s Expanded Access Program continues to provide SL1009 to eligible patients, ensuring that those in need have access to this investigational therapy while regulatory discussions proceed.
Policy Significance
The FDA’s issuance of the CRL highlights the agency’s rigorous standards in evaluating treatments for rare diseases. It also underscores the importance of clear communication between regulatory bodies and pharmaceutical companies. The ongoing dialogue between Saol and the FDA may set precedents for the development and approval processes of treatments for ultra-rare conditions, influencing future policy decisions in the field of orphan drug development.
While the FDA’s Complete Response Letter for SL1009 presents challenges, it also opens avenues for constructive dialogue between Saol Therapeutics and the agency. The company’s commitment to addressing the FDA’s observations and seeking alternative approval pathways reflects a dedication to bringing much-needed therapies to patients with PDCD. The outcome of these discussions will be pivotal in shaping the future of SL1009 and its potential to become the first FDA-approved treatment for this debilitating condition.
Source: Saol Therapeutics Press Release
